Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

Part of paid clinical trials in Chicago, Illinois.

Sponsor: Northwestern University
Study ID: NCT06684522
Phase: EARLY_PHASE1
Status: Recruiting

Apply to this trial

Conditions

Eyelid Dermatitis

Eligibility Criteria

Sex: ALL
Age: 18 Years - 70 Years
Healthy Volunteers: Not accepted

Interventions

Upadacitinib 15 MG — DRUG
Upadacitinib 15mg daily

Study Details

This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.

Key Dates

Start date: Dec 18, 2025
Status verified: May 2026
Primary completion: Jun 30, 2027
Completion: Jun 30, 2027

Study Design

Enrollment: 10 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Upadacitinib Treatment
Participants on upadacitinib 15mg daily

Primary Outcome Measure

Reduction in Investigator Global Assessment (IGA) [ Time Frame: 12 weeks ]

Central Contacts

Dermatology CTU
312-503-5944
[email protected]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Northwestern University Department of Dermatology	Chicago	Illinois	60611	Dermatology CTU [email protected]

Find similar trials in Chicago, IL

By research site

Northwestern University Department of Dermatology· Chicago, IL